Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Vaccination of immunocompromised individuals: Expert opinion - update 2026].

Wiener klinische Wochenschrift·2026
Same author

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same author

Correction: Antibacterial effects of coniferyl alcohol-derived dehydrogenation polymer on chlamydial infection <i>in vitro</i>.

Frontiers in chemistry·2026
Same author

Antibacterial effects of coniferyl alcohol-derived dehydrogenation polymer on chlamydial infection <i>in vitro</i>.

Frontiers in chemistry·2025
Same author

Antibody Responses Following Primary Immunization with the Recombinant Herpes Zoster Vaccine (Shingrix<sup>®</sup>) in VZV Seronegative Immunocompromised Adults.

Vaccines·2025
Same author

<i>Trichinella spiralis</i>-derived extracellular vesicles induce regulatory T cells and reduce airway allergy in mice.

Frontiers in immunology·2025

Related Experiment Video

Updated: Jun 20, 2026

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

Hitting the mucosal road in tolerance induction.

Ursula Wiedermann1

  • 1Department of Specific Prophylaxis and Tropical Medicine, Center for Physiology and Pathophysiology, Medical University Vienna, Vienna, Austria. ursula.wiedermann@meduniwien.ac.at

Nestle Nutrition Workshop Series. Paediatric Programme
|August 28, 2009
PubMed
Summary
This summary is machine-generated.

New allergy vaccines aim to induce mucosal tolerance, offering a promising treatment for allergic disorders. Research explores parasitic molecules as adjuvants to enhance vaccine efficacy in mouse models.

More Related Videos

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

Related Experiment Videos

Last Updated: Jun 20, 2026

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

Area of Science:

  • Immunology
  • Allergy Research
  • Vaccine Development

Background:

  • Allergic diseases have significantly increased in Westernized societies, affecting 25-30% of the population.
  • Factors like reduced early-life microbial exposure and nutritional changes may contribute to this rise.
  • Current specific immunotherapy for type-I allergies is limited in older or multisensitized patients.

Purpose of the Study:

  • To develop novel allergy vaccines utilizing the principle of mucosal tolerance induction.
  • To investigate the potential of genetically engineered allergen constructs for allergy prevention.
  • To explore parasitic molecules as adjuvants for enhancing allergy vaccine efficacy.

Main Methods:

  • Development of genetically engineered allergen constructs for mucosal administration.
  • Testing of these constructs in mouse models of respiratory allergy.
  • Evaluation of mucosal adjuvants and parasitic molecules for improved therapeutic outcomes.

Main Results:

  • Mucosal treatment with engineered allergen constructs prevented allergic sensitivities in mouse models.
  • The use of mucosal adjuvants showed promise in improving therapeutic approaches.
  • Parasitic molecules with immunosuppressive properties are being investigated as potential vaccine adjuvants.

Conclusions:

  • Novel allergy vaccines based on mucosal tolerance induction are a promising therapeutic strategy.
  • Genetically engineered allergen constructs and parasitic adjuvants represent innovative approaches to allergy treatment.
  • Further research is needed to translate these findings into effective treatments for human allergic diseases.